What is Spiolto® Respimat® (tiotropium/olodaterol)?

Tiotropium/olodaterol is approved as once daily maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD. It is built on tiotropium, the active ingredient in Spiriva® and is enhanced by olodaterol which was specifically designed to complement the efficacy of tiotropium. Tiotropium/olodaterol provides significant improvements in lung function, COPD symptoms and quality of life over tiotropium – right from the initial stages when suitable patients need maintenance therapy.[1-4]

Tiotropium/olodaterol is administered via Respimat®, the only inhaler available that actively delivers a unique mist. This means the patient just needs to take a slow deep breath to get the medication deep into the lungs.*[5-9]

What is the safety profile of Spiolto® Respimat® (tiotropium/olodaterol)?

Spiolto® Respimat® (tiotropium/olodaterol) has a comparable adverse event profile to the component monotherapies.[10]

Adverse event incidence was generally balanced across all treatment groups, with the majority being mild to moderate in severity.[10]

Spiolto® Respimat® safety and tolerability profile was established in patients treated for up to 52 weeks.[10]

The proportion of patients who discontinued due to adverse events with Spiolto® Respimat® was comparable to that of Spiriva® (tiotropium) and Striverdi® (olodaterol).[10]

The percentage of patients reporting an adverse event with Spiolto® Respimat® was comparable to that of Spiriva®.[10]

For full safety profile, please refer to the Local Prescribing Information.

What are the contraindications of Spiolto® Respimat® (tiotropium/olodaterol)?[4]

Spiolto® Respimat® is contraindicated in patients with hypersensitivity to tiotropium or olodaterol or to any of the excipients.

Spiolto® Respimat® is also contraindicated in patients with a history of hypersensitivity to atropine or its derivatives, e.g. ipratropium or oxitropium.